PubMed Health⌕ Search

PubMed · 11040134

Expression and coreceptor function of APJ for primate immunodeficiency viruses.

Abstract

APJ is a seven transmembrane domain G-protein-coupled receptor that functions as a coreceptor for some primate immunodeficiency virus strains. The in vivo significance of APJ coreceptor function remains to be elucidated, however, due to the lack of an antibody that can be used to assess APJ expression, and because of the absence of an antibody or ligand that can block APJ coreceptor activity. Therefore, we produced a specific monoclonal antibody (MAb 856) to APJ and found that it detected this receptor in FACS, immunofluorescence, and immunohistochemistry studies. MAb 856 also recognized APJ by Western blot, enabling us to determine that APJ is N-glycosylated. Using this antibody, we correlated APJ expression with coreceptor activity and found that APJ had coreceptor function even at low levels of expression. However, we found that APJ could not be detected by FACS analysis on cell lines commonly used to propagate primate lentiviruses, nor was it expressed on human PBMC cultured under a variety of conditions. We also found that some viral envelope proteins could mediate fusion with APJ-positive, CD4-negative cells, provided that CD4 was added in trans. These findings indicate that in some situations APJ use could render primary cell types susceptible to virus infection, although we have not found any evidence that this occurs. Finally, the peptide ligand for APJ, apelin-13, efficiently blocked APJ coreceptor activity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B A Puffer, M Sharron, C M Coughlan, F Baribaud, C M McManus, B Lee, J David, K Price, R Horuk, M Tsang, R W Doms. 2000-10-25. Expression and coreceptor function of APJ for primate immunodeficiency viruses.. https://doi.org/10.1006/viro.2000.0557

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Increased expression of chitinase 3-like protein 1 secondary to joint immobility.

Previous studies have established mechanical stimulation of joints is necessary to maintain the structure and function of the articular cartilage. Immobilization of the rat knee joint induces cartilage degeneration and reduces the joint range of motion, two of the clinical parameters used to define a joint contracture. We hypothesized chondrocytes from articular cartilage increase their expression of the chitinase 3-like protein 1 (CHI3L1) gene in response to joint immobility. We selected the CHI3L1 gene on the basis of its identification as a differentially expressed gene in the articular cartilage obtained from immobilized rat knee joints. Expression of CHI3L1 mRNA was increased after 2 and 4 weeks of immobility. A time-course study revealed that CHI3L1 immuno-reactivity was increased at 2 and 4 weeks and return to basal levels at all later time points. CHI3L1 gene adds to the list of differentially expressed genes defining the response of cartilage to joint immobility. Our data confirm a protective role for CHI3L1 in the initial phase of degeneration induced by immobility.

Adipokines↗

Is YKL-40 a new therapeutic target in cancer?

YKL-40 is produced by cancer cells and tumour-associated macrophages. YKL-40 may play a role in cancer cell proliferation, differentiation, survival, invasiveness, metastasis, in angiogenesis and the inflammation and remodelling of the extracellular matrix surrounding the tumour. Serum YKL-40 is a biomarker of prognosis, confirmed in 13 different types of cancer including > 2500 patients. Highest serum YKL-40 is found in patients with metastatic cancer with the shortest recurrence-free interval and shortest overall survival. Serum YKL-40 provides independent information compared with clinical characteristics and biomarkers, such as HER2, carcinoembryonic antigen, CA-125, prostate-specific antigen and lactate dehydrogenase. The authors hypothesise that inhibition of YKL-40 by monoclonal antibodies either directly or towards its receptor may be as efficient a cancer therapeutic as the monoclonal antibodies against HER2, HER1, vascular endothelial growth factor and CD20. Drugs inhibiting YKL-40 should be explored as new cancer therapeutics.

Adipokines↗

Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.

PPAR-alpha agonists improve insulin sensitivity in rodent models of obesity/insulin resistance, but their effects on insulin sensitivity in humans are less clear. We measured insulin sensitivity by hyperinsulinemic-isoglycemic clamp in 10 obese females with type 2 diabetes before and after three months of treatment with PPAR-alpha agonist fenofibrate and studied the possible role of the changes in endocrine function of adipose tissue in the metabolic effects of fenofibrate. At baseline, body mass index, serum glucose, triglycerides, glycated hemoglobin and atherogenic index were significantly elevated in obese women with type 2 diabetes, while serum HDL cholesterol and adiponectin concentrations were significantly lower than in the control group (n=10). No differences were found in serum resistin levels between obese and control group. Fenofibrate treatment decreased serum triglyceride concentrations, while both blood glucose and glycated hemoglobin increased after three months of fenofibrate administration. Serum adiponectin or resistin concentrations were not significantly affected by fenofibrate treatment. All parameters of insulin sensitivity as measured by hyperinsulinemic-isoglycemic clamp were significantly lower in an obese diabetic group compared to the control group before treatment and were not affected by fenofibrate administration. We conclude that administration of PPAR-alpha agonist fenofibrate for three months did not significantly affect insulin sensitivity or resistin and adiponectin concentrations in obese subjects with type 2 diabetes mellitus. The lack of insulin-sensitizing effects of fenofibrate in humans relative to rodents could be due to a generally lower PPAR-alpha expression in human liver and muscle.

Adipokines↗